Dear NNPDF Families and Friends,
The NNPDF Central Offices have been notified that Genzyme, a Sanofi Company, has released a statement with additional details about the pediatric Phase 1 / 2 clinical trial of recombinant human acid sphingomyelinase (rhASM).
Visit the NNPDF Enzyme Replacement Therapy web page to view the the statement: http://www.nnpdf.org/npresearch_11.html#Apr24th2015
No comments:
Post a Comment